A Study to Evaluate the Efficacy and Safety of AD-218

Launched by ADDPHARMA INC. · May 27, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called AD-218 for people with mixed dyslipidemia, which is a condition that affects cholesterol and fat levels in the blood. The main goal is to see how well AD-218 works and if it is safe for patients. The trial is currently looking for participants who are at least 19 years old, and both men and women can join. Before taking part, you would need to sign a consent form to show that you understand the study.

If you decide to participate, you can expect to receive the treatment and be monitored by healthcare professionals throughout the trial. It's important to know that some individuals may not be eligible to join if they have certain health conditions, such as fibromyalgia or muscle disorders. Overall, this study aims to find a better way to manage mixed dyslipidemia and improve health outcomes for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • A man or woman over 19 years old.
• • Sign on ICF prior to study participation
• Exclusion Criteria:
• • History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN)
• • Other exclusions applied